Results 241 to 250 of about 543,312 (350)

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Left bundle branch area pacing with stylet driven lead in third-degree atrioventricular block following Morrow surgery

HeartRhythm Case Reports
Bambagioni Gabriele, MD, Ricciardi Giuseppe, MD, PhD, Pieragnoli Paolo, MD, PhD, Perrotta Laura, MD, PhD, Beltrami Matteo, MD, PhD, Fabio Daniele Brogni, MD, Checchi Luca, MD   +6 more
doaj   +1 more source

Long-Term Cardiovascular and Mortality Risk in Patients with Pre-Existing Arrhythmia Post-SARS-CoV-2 Infection. [PDF]

Diagnostics (Basel)
Pahuja S, Hadidchi R, Tonge J, Henry S, Duong TQ.   +4 more
europepmc   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Resolution of Fetal Arrhythmia Following Maternal Discontinuation of Doxylamine (Unisom): A Case Report and Review. [PDF]

Cureus
Ponton OL, Ashwath R, Paudel G.
europepmc   +1 more source

An inherited life-threatening arrhythmia model established by screening randomly mutagenized mice [PDF]

Yuta Okabe, Nobuyuki Murakoshi, Nagomi Kurebayashi, H. Inoue, Yoko Itō, Takashi Murayama, Chika Miyoshi, Hiromasa Funato, Koichiro Ishii, Dongzhu Xu, Kazuko Tajiri, Rujie Qin, Kazuhiro Aonuma, Yoshiko Murakata, Zonghu Song, Shigeharu Wakana, Utako Yokoyama, Takashi Sakurai, Kazutaka Aonuma, Masaki Ieda, Masashi Yanagisawa   +20 more
openalex   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Prevalence of arrhythmias and associated factors among COVID-19 patients in the intensive care unit at COVID-19 treatment centers, Addis Ababa, Ethiopia, 2022. A cross-sectional study. [PDF]

BMC Infect Dis
Letemu G, Mengistu Z, WoldeMariam EB.
europepmc   +1 more source

Updates in Arrhythmia Management in Adult Congenital Heart Disease [PDF]

Adam J. Small, Matthew Dai, Dan G. Halpern, Reina Bianca Tan   +3 more
openalex   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source